Comparison of Video-Assisted Thoracoscopic Surgery and Robotic Approaches for Clinical Stage I and Stage II Non-Small Cell Lung Cancer Using The Society of Thoracic Surgeons Database
Overview
Pulmonary Medicine
Authors
Affiliations
Background: Data from selected centers show that robotic lobectomy is safe and effective and has 30-day mortality comparable to that of video-assisted thoracoscopic surgery (VATS). However, widespread adoption of robotic lobectomy is controversial. We used The Society of Thoracic Surgeons General Thoracic Surgery (STS-GTS) Database to evaluate quality metrics for these 2 minimally invasive lobectomy techniques.
Methods: A database query for primary clinical stage I or stage II non-small cell lung cancer (NSCLC) at high-volume centers from 2009 to 2013 identified 1,220 robotic lobectomies and 12,378 VATS procedures. Quality metrics evaluated included operative morbidity, 30-day mortality, and nodal upstaging, defined as cN0 to pN1. Multivariable logistic regression was used to evaluate nodal upstaging.
Results: Patients undergoing robotic lobectomy were older, less active, and less likely to be an ever smoker and had higher body mass index (BMI) (all p < 0.05). They were also more likely to have coronary heart disease or hypertension (all p < 0.001) and to have had preoperative mediastinal staging (p < 0.0001). Robotic lobectomy operative times were longer (median 186 versus 173 minutes; p < 0.001); all other operative measurements were similar. All postoperative outcomes were similar, including complications and 30-day mortality (robotic lobectomy, 0.6% versus VATS, 0.8%; p = 0.4). Median length of stay was 4 days for both, but a higher proportion of patients undergoing robotic lobectomy had hospital stays less than 4 days (48% versus 39%; p < 0.001). Nodal upstaging overall was similar (p = 0.6) but with trends favoring VATS in the cT1b group and robotic lobectomy in the cT2a group.
Conclusions: Patients undergoing robotic lobectomy had more comorbidities and robotic lobectomy operative times were longer, but quality outcome measures, including complications, hospital stay, 30-day mortality, and nodal upstaging, suggest that robotic lobectomy and VATS are equivalent.
Song M, Liu Q, Guo H, Wang Z, Zhang H J Robot Surg. 2024; 19(1):33.
PMID: 39729231 DOI: 10.1007/s11701-024-02203-2.
Lin S, Yu X, Xu Y, Xin Y, He J, Yu Z Thorac Cancer. 2024; 16(1):e15500.
PMID: 39603599 PMC: 11729994. DOI: 10.1111/1759-7714.15500.
Uno Y, Tane S, Tanaka Y, Takanashi M, Doi T, Ogawa H Surg Today. 2024; .
PMID: 39540928 DOI: 10.1007/s00595-024-02957-0.
Lee J, Gu B, Yong H, Hwang S, Kim H Cancers (Basel). 2024; 16(17).
PMID: 39272949 PMC: 11394038. DOI: 10.3390/cancers16173091.
Pan J, Watkins A, Stock C, Moffatt-Bruce S, Servais E Cancers (Basel). 2024; 16(17).
PMID: 39272946 PMC: 11393871. DOI: 10.3390/cancers16173086.